Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DXCM vs GEHC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXCM Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

DXCM Overall Winner 6-Pillar Tally: DXCM 3 – 3 GEHC Matrix Metrics: DXCM 5 – 5 GEHC

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over GE HealthCare Technologies Inc. (GEHC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas GEHC carries 38.6/100 (SELL) at $80.64 (14.7x Forward P/E, 13.8% operating margin).

  • Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile GEHC trades in a Markup technical trend (SURGE options phase, RSI 56.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXCM vs GEHC
DXCM NASDAQ Head-to-Head Winner
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap $29.9B
TTM Revenue $5.10B
Forward P/E 25.3x
Beta / 30D Vol 0.59β · 43% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.3%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $81.49 · SMA50: $83.94
GEHC NASDAQ
GE HealthCare Technologies Inc. Common Stock
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$80.64
-1.53% 1D
Market Cap $37.0B
TTM Revenue $21.6B
Forward P/E 14.7x
Beta / 30D Vol 0.52β · 39% Vol
Unified Composite Score
38.6 / 100 SELL
Tech 29.0 Fund 44.0 Flow 59.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.6% over 20 days), RSI 56
RSI-14: 56.4 · SMA20: $80.51 · SMA50: $72.19

6-Pillar Scorecard Institutional Category Breakdown (DXCM 3 – 3 GEHC)

Columns: Metric · DXCM · GEHC
1. Valuation Multiples GEHC
Forward P/E 25.3x 14.7x
Trailing P/E 31.6x 17.3x
PEG Ratio 1.30x 2.24x
EV / Revenue 5.9x 2.1x
2. Growth & Scale GEHC
Revenue Growth (YoY) +11.2% +7.2%
Earnings Growth (YoY) +2.6% +39.0%
TTM Revenue (USD) $5.10B $21.6B
Market Cap $29.9B $37.0B
3. Profitability & Quality DXCM
Gross Margin 63.4% 39.3%
Operating Margin 24.0% 13.8%
Net Profit Margin 19.4% 10.0%
Return on Equity (ROE) 37.7% 20.0%
4. Balance Sheet & Cash Flow DXCM
Cash Generation (TTM) $1.73B $1.89B
Cash Flow Margin 33.9% 8.7%
Net Cash / Leverage $432M Net Debt (0.55x D/E) $7.58B Net Debt (0.90x D/E)
Dividend Yield None (0.00%) 0.17%
5. Options & Positioning GEHC
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 63.0% (15th %ile) 58.6% (8th %ile)
Put/Call OI Skew 0.48x (Call-Skewed) 0.28x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat DXCM
OpEx & R&D Intensity 39.4% of Rev ($2.01B) 25.5% of Rev ($5.52B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXCM (5) vs GEHC (5)
Institutional Metric DXCM GEHC Criterion Row Edge
Market Capitalization
Scale
$29.9B $37.0B Larger Scale GEHC
Trailing P/E Ratio
Valuation
31.6x 17.3x Lower Multiple GEHC
Forward P/E Ratio
Valuation
25.3x 14.7x Lower Multiple GEHC
Revenue Growth (YoY)
Growth
+11.2% +7.2% Higher Growth DXCM
Operating Margin (TTM)
Profitability
24.0% 13.8% Higher Margin DXCM
Net Profit Margin
Profitability
19.4% 10.0% Higher Margin DXCM
Return on Equity (ROE)
Capital Efficiency
37.7% 20.0% Higher ROE DXCM
52-Week Range Position
Momentum
63% ($57–$93) 71% ($59–$90) Stronger Trend GEHC
Beta / 30D Volatility
Risk Regime
0.59β · 43% Vol 0.52β · 39% Vol Lower Realized Risk GEHC
Unified Institutional Score
Composite Signal
50.8 / 100 (HOLD) 38.6 / 100 (SELL) Higher Composite DXCM
Trailing 12M Revenue (USD)
Operating Scale
$5.10B $21.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.4% 39.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.30x PEG · 5.9x EV/Rev 2.24x PEG · 2.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.73B ($432M Net Debt (0.55x D/E)) $1.89B ($7.58B Net Debt (0.90x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GEHC +11.63 pp
DXCM: +1.28% · GEHC: +12.91%
3M Horizon GEHC +21.58 pp
DXCM: -12.89% · GEHC: +8.69%
6M Horizon GEHC +15.54 pp
DXCM: +10.01% · GEHC: +25.55%
1Y Horizon DXCM +21.28 pp
DXCM: +32.8% · GEHC: +11.52%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DXCM Revenue GEHC Revenue DXCM Op. Margin GEHC Op. Margin Margin Leader
FY2018 $1.03B N/A -18.1% N/A DXCM
FY2019 $1.48B N/A 9.6% N/A DXCM
FY2020 $1.93B N/A 15.5% N/A DXCM
FY2021 $2.45B $17.6B 10.9% 15.9% GEHC
FY2022 $2.91B $18.3B 13.4% 13.8% GEHC
FY2023 $3.62B $19.6B 16.5% 12.5% DXCM
FY2024 $4.03B $19.7B 14.9% 13.3% DXCM
FY2025 $4.66B $20.6B 19.6% 13.4% DXCM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXCM CONSOLIDATION
73d in phase · OBV ACCUMULATION
Current IV 63.0%
IV Percentile 15th %ile
Put/Call OI Skew 0.48x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DXCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GEHC SURGE
12d in phase · OBV DISTRIBUTION
Current IV 58.6%
IV Percentile 8th %ile
Put/Call OI Skew 0.28x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact GEHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $81.61 · IV 39.6%

DXCM vs. GEHC: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of DXCM ($8,161) vs. GEHC ($8,296) against risk-defined 5-day vertical and put-wall option structures.

DXCM Spot $81.61 · IV 39.6%
DXCM Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $80 / $90 Bull Call Spread

Buy 1x $80C · Sell 1x $90C · 31d

Net Entry $482 Debit
T+5d @ +5% Move +$136 (+28%)
Max Risk / Buffer $482 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $75 / $70 Bull Put Spread

Sell 1x $75P · Buy 1x $70P · 31d

Net Entry $86 Credit
Max Credit / Yield +$86 (+20.8% RoM)
Max Risk / Buffer -9.2% Cushion ($414 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
GEHC Spot $82.96 · IV 29.7%
GEHC Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $82.5 / $87.5 Bull Call Spread

Buy 1x $82.5C · Sell 1x $87.5C · 32d

Net Entry $222 Debit
T+5d @ +5% Move +$109 (+49%)
Max Risk / Buffer $222 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $77.5 / $72.5 Bull Put Spread

Sell 1x $77.5P · Buy 1x $72.5P · 32d

Net Entry $87 Credit
Max Credit / Yield +$87 (+21.1% RoM)
Max Risk / Buffer -7.6% Cushion ($413 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXCM Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $29.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 39.4% of Rev ($2.01B)
90D Engineering Disclosures 0 Published
GEHC Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $37.0B market capitalization and 13.8% operating margin.
OpEx & R&D Reinvestment 25.5% of Rev ($5.52B)
90D Engineering Disclosures 0 Published

Investor FAQ DXCM vs GEHC Key Questions & Quantitative Answers

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over GE HealthCare Technologies Inc. (GEHC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas GEHC carries 38.6/100 (SELL) at $80.64 (14.7x Forward P/E, 13.8% operating margin). Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile GEHC trades in a Markup technical trend (SURGE options phase, RSI 56.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GEHC leads the Growth & Scale pillar: DXCM posts +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin), compared with GEHC at +7.2% YoY revenue growth and +39.0% YoY earnings growth on $21.6B TTM revenue (39.3% gross margin, 13.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DXCM cumulative revenue shifted +352.4% while GEHC shifted +17.2%. In operating R&D and SG&A reinvestment, DXCM deploys 39.4% of Rev ($2.01B) (0 90-day corporate R&D disclosures) versus 25.5% of Rev ($5.52B) (0 disclosures) for GEHC.

GEHC screens cheaper on headline valuation multiples. DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin), whereas GEHC trades at 14.7x Forward P/E, 17.3x Trailing P/E, 2.24x PEG, and 2.1x EV/Revenue (8.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXCM (37.7% ROE) versus GEHC (20.0% ROE) capital efficiency.

In options market volatility and institutional positioning, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk). By comparison, GEHC carries 58.6% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.28x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.52β · 39% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.